A dramatic clinical improvement experienced by an HIV-infected patient developing PML-IRIS—a case which could not be included in our review—was reported when maraviroc, an antagonist of CCR5, was added to ART (58). This evidence concerns the gene CCR5 and progressive multifocal leukoencephalopathy.